<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438345</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 140 2102</org_study_id>
    <nct_id>NCT02438345</nct_id>
  </id_info>
  <brief_title>PRO 140 for Human Immunodeficiency Virus</brief_title>
  <official_title>A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRO 140 2102 is a multicenter, randomized, double-blind, placebo-controlled, clinical trial&#xD;
      of observed systemic, long-acting, anti-HIV treatment with a monoclonal CCR5 antibody (PRO&#xD;
      140) as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection&#xD;
      drug users with viral rebound and documented poor adherence to the previous antiretroviral&#xD;
      regimen. Eligible subjects (approximately 76) will be randomized 1:1 to receive an optimized&#xD;
      background antiretroviral regimen (OBR) plus supervised weekly subcutaneous treatment with&#xD;
      either PRO 140 or placebo. Blood samples for safety and efficacy variables will be obtained&#xD;
      over the 24 week duration of the study. Safety will be monitored throughout the course of the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects without virologic failure at week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRO 140: one SC dose, 350 mg, weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PRO 140: one SC dose, placebo, weekly for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRO 140</intervention_name>
    <description>Humanized monoclonal antibody to CCr5</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Exclusive CCR5-tropic virus as determined by as determined by the Enhanced Sensitivity&#xD;
             Trofile™ HIV Tropism Assay&#xD;
&#xD;
          2. Males and females, age ≥ 18 years&#xD;
&#xD;
          3. Screening plasma HIV-1 RNA &gt; 1,000 copies/mL confirmed by second test while on the&#xD;
             current antiretroviral regimen&#xD;
&#xD;
          4. History of non-prescription injection and/or non-injection recreational drug use&#xD;
&#xD;
          5. CD4 lymphocyte cell counts &gt; 100 cells/mm3&#xD;
&#xD;
          6. Clinically normal resting 12-lead ECG at screening visit&#xD;
&#xD;
          7. Women of reproductive potential must have a negative serum pregnancy test at Late&#xD;
             Screening Visit. Within hours prior to receiving the first dose of study drug, women&#xD;
             of reproductive potential must have a negative urine pregnancy test. Male and female&#xD;
             subjects must agree not to participate in a conception process and agree to use one&#xD;
             barrier method of contraception plus one other highly reliable contraceptive method&#xD;
             from the early screening visit through week 24.&#xD;
&#xD;
          8. Non-adherent, history of poor adherence to a previous antiretroviral regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CXCR4-tropic virus, dual/mixed tropic (R5X4) virus as determined by the Enhanced&#xD;
             Sensitivity Trofile™ HIV Tropism Assay&#xD;
&#xD;
          2. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant&#xD;
             during the study&#xD;
&#xD;
          3. Diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A&#xD;
             or a new diagnosis of hepatitis B or C within 24 weeks of dosing)&#xD;
&#xD;
          4. Prior use of any entry, attachment, CCR5 coreceptor, or fusion inhibitor, including&#xD;
             PRO 140, experimental or approved&#xD;
&#xD;
          5. Participation in an experimental drug trial(s) within 30 days of the early screening&#xD;
             visit or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Phildadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leronlimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

